An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder
J Clin Psychiatry 2001;62(4):290-294
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: An open-label trial was performed to
explore efficacy and safety of olanzapine, an atypical
neuroleptic with diverse receptor activity including both
dopamine-2 and serotonin-2A and -2C antagonism, for treatment of
Method: Ten adult patients aged 20 to 44 years
with Tourette's disorder were treated using an open-label,
flexible dosing schedule for 8 weeks. Three patients who
continued olanzapine were reevaluated after 6 months. Three
subjects were psychotropic medication naive, 5 patients
experienced intolerable side effects with conventional
neuroleptics, and 2 patients had remote (>= 10 years)
successful response to conventional neuroleptics. Tic severity
was rated by the Yale Global Tic Severity Scale; weight, vital
signs, and adverse effects were assessed weekly.
Electrocardiogram, laboratory studies, and comorbid symptoms,
assessed by the Yale-Brown Obsessive Compulsive Scale and ADHD
Behavior Checklist for Adults, were measured at baseline and at
Results: Two of 10 patients prematurely
discontinued olanzapine owing to excessive sedation. Of 8
patients who completed the 8-week trial, 4 (50%) demonstrated
reduction of global tic severity scores by >= 20 points, and 6
(75%) demonstrated reductions by >= 10 points. No significant
changes in comorbid symptoms were demonstrated. Sedation, weight
gain, increased appetite, dry mouth, and transient asymptomatic
hypoglycemia were the most common side effects. Tic improvements
were maintained in 3 patients reassessed 6 months later. Final
olanzapine dosages ranged from 2.5 mg to 20 mg daily (mean = 10.9
Conclusion: This open-label study suggests that
olanzapine should be explored as a potential alternative to
conventional neuroleptic medications for treatment of motor tics
and Tourette's disorder.